GeneThera Retains crowdSPRING for New Corporate Logo and Branding Campaign
15 Gennaio 2009 - 9:02PM
Marketwired
GeneThera, Inc. (PINKSHEETS: GTHR) announced today it has secured
the services of crowdSPRING, based in Chicago, to develop the
company's new logo and company branding symbols.
GeneThera chose the theme "New Beginning" due to the new
beginnings within biotechnology and the company itself. Recently,
GeneThera stated it was moving from being focused on R&D to
focusing on revenue generating. As part of this transformation, the
company is currently re-designing its corporate branding and image,
which will be incorporated in its new website. The new
GeneThera.net site should be finished by the end of January.
"We want a young, vibrant, and forward-looking feel with our
logo and branding," noted Tony Milici. "One of the interesting
approaches crowdSPRING uses is by letting all interested graphic
designers submit their entry for a logo they feel suits our needs.
The public will be able to view all entries and vote for their
favorite. This new logo will be incorporated into our website,
brochures, PowerPoint presentations, press kits, upcoming YouTube
videos, and more. This is truly a collaborative process."
All interested graphics designers need to go to the following
webpage in order to submit their entry:
http://www.crowdspring.com/projects/graphic_design/logo/bio_tech_company_involved_in_
genetic_vaccines_needs_modern_logo
Once there, simply click on the "Participate Now" link on the
right.
For the public to vote on their favorite logo, please go to the
same webpage:
http://www.crowdspring.com/projects/graphic_design/logo/bio_tech_company_involved_in_
genetic_vaccines_needs_modern_logo
Simply view the entries as they are received, click on them for
more details and click on the "People love it" link below the image
to cast your vote.
Please feel free to vote on as many as you like, as often as you
like. The winning entry will be announced Tuesday, January
20th.
ABOUT GENETHERA, INC.
GeneThera, Inc. is a molecular biotechnology company located in
Wheat Ridge, Colorado. The Company's proprietary diagnostic
solution is based on a genetic expression assay, GES(TM), a
protocol designed to function on a highly automated Fluorogenic PCR
platform. This platform enables GeneThera to offer tests that are
presently not available from other technologies. The GES is
designed for a host of individual diseases, the current priorities
being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For
more information, contact Al Goldsmith of The Goldsmith Group LLC
at 303-463-6371 Ext. 206.
This press release contains forward-looking statements, which
are made pursuant to the Safe-Harbor provisions of the Private
Securities Litigation Reform Act of 1995. Words such as "intends,"
"believes," and similar expressions reflecting something other than
historical fact are intended to identify forward-looking
statements, but are not the exclusive means of identifying such
statements. These forward-looking statements involve a number of
risks and uncertainties, including the timely development and
market acceptance of products and technologies, the ability to
secure additional sources of finance, the ability to reduce
operating expenses, and other factors described in the Company's
filings with the Securities and Exchange Commission. The actual
results that the Company achieves may differ materially from any
forward-looking statement due to such risks and uncertainties. The
Company undertakes no obligation to revise or update any
forward-looking statements in order to reflect events or
circumstances that may arise after the date of this release.
Dr. Tony Milici 303-463-6371 Goldsmith Group 303-838-4370 JR
Dopkin & Associates 516-884-3200
Grafico Azioni GeneThera (CE) (USOTC:GTHR)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni GeneThera (CE) (USOTC:GTHR)
Storico
Da Giu 2023 a Giu 2024